Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glaucoma and Ocular Hypertension Clear all
Recruiting Phase 3 Interventional

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

NCT05401357
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
9
States / cities
Newport Beach, California • Petaluma, California • New Smyrna Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 13, 2026, 5:54 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Retinal Blood Flow and Autoregulation

NCT05344274
View directory record Official record
Conditions
Glaucoma
Interventions
Indocyanine Green Angiography, Isocapnic Oxygen, Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)
Diagnostic Test · Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 13, 2026, 5:54 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

NCT05127525
View directory record Official record
Conditions
Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions
IRX-101, Control
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 13, 2026, 5:54 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Eye Health Intervention Study in Upper Manhattan

NCT06112431
View directory record Official record
Conditions
Glaucoma, Suspect, Diabetic Retinopathy, Cataract, Refractive Errors, Vision Impairment and Blindness
Interventions
Intervention, Usual Care
Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 13, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT02136940
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 13, 2026, 5:54 PM EDT
Terminated Phase 1 Interventional

Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension

NCT04500574
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost eluting contact lens, Topical Latanoprost
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 13, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT04630808
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
NCX 470 0.1%, Latanoprost 0.005%
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
63
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 13, 2026, 5:54 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

African Descent and Glaucoma Evaluation Study

NCT00221923
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 13, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

NCT03691649
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 13, 2026, 5:54 PM EDT
Completed No phase listed Observational

Survey of Patients Taking IOP-Lowering Eye Drops

NCT02384772
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Survey
Other
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 13, 2026, 5:54 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

NCT06369077
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions
dorzolamide/timolol
Drug
Lead sponsor
CT Glaucoma Associates
Other
Eligibility
25 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 13, 2026, 5:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A More Engaging Visual Field Test to Increase Use and Reliability in Pediatrics

NCT02157025
View directory record Official record
Conditions
Glaucoma, Suspect, Optic Nerve Hypoplasia and Abnormalities of the Central Nervous System, Congenital Coloboma of the Optic Nerve, Optic Nerve Head Pits, Bilateral Congenital
Interventions
Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry, Usual Care procedures during Humphrey perimetry for children
Device · Other
Lead sponsor
Nova Southeastern University
Other
Eligibility
5 Years to 8 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 13, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

NCT04284514
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 13, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

NCT01001195
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2013 · Synced Oct 13, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

NCT04405245
View directory record Official record
Conditions
Ocular Hypertension, Primary Open Angle Glaucoma
Interventions
Latanoprost ophthalmic solution, AKB-9778 4%, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
21
States / cities
Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 13, 2026, 5:54 PM EDT
Completed Phase 2 Interventional

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

NCT01481077
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension (OH)
Interventions
Latanoprost-PPDS
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Springdale, Arkansas • Denver, Colorado • Danbury, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 13, 2026, 5:54 PM EDT
Recruiting Phase 4 Interventional

Rocklatan vs Latanoprost Post-DSLT

NCT07465913
View directory record Official record
Conditions
Glaucoma
Interventions
Rocklatan 0.02%-0.005% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Eye Centers of Southeast Texas
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beaumont, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 13, 2026, 5:54 PM EDT
Not listed Phase 1 Interventional

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

NCT06267274
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 13, 2026, 5:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Does the Optic Disc Grading Done Visually by Your Doctor Agree With Optic Nerve Testing Which is Done by Machines?

NCT00430287
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
45 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 13, 2026, 5:54 PM EDT
Completed Not applicable Interventional Results available

The Effects of an Antioxidant Formulation on Ocular Blood Flow

NCT01930487
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
dietary supplement with antioxidants, Placebo
Dietary Supplement
Lead sponsor
ScienceBased Health
Industry
Eligibility
30 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 13, 2026, 5:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging

NCT00556114
View directory record Official record
Conditions
Glaucoma, Diabetic Retinopathy, Age-Related Macular Degeneration, Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
Optical Coherence Tomography
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 13, 2026, 5:54 PM EDT
Terminated Not applicable Interventional

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

NCT03016156
View directory record Official record
Conditions
Retinoblastoma, Cataracts Infantile, Glaucoma, Congenital, Leucocoria
Interventions
CRADLE, Red reflex testing
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 7 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 13, 2026, 5:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

OCT Agreement and Crossed Precision Study

NCT02050880
View directory record Official record
Conditions
Glaucoma, Retinal Disease, Corneal Disease
Interventions
Not listed
Lead sponsor
Nidek Co. LTD.
Industry
Eligibility
20 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 13, 2026, 5:54 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Glaucoma Screening to Enhance At-Risk Californians' Health

NCT06854198
View directory record Official record
Conditions
Glaucoma
Interventions
Glaucoma screening with optical coherence tomography (OCT), color fundus photography, and tonometry, Educational Brochure
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 13, 2026, 5:54 PM EDT